Andrew Liu
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 95 | 2025 | 1805 | 8.360 |
Why?
| | Hypersensitivity | 16 | 2023 | 254 | 3.170 |
Why?
| | Urban Population | 18 | 2024 | 502 | 2.910 |
Why?
| | Anti-Asthmatic Agents | 16 | 2024 | 264 | 1.720 |
Why?
| | Environmental Exposure | 10 | 2025 | 583 | 1.460 |
Why?
| | Severity of Illness Index | 18 | 2025 | 2974 | 1.180 |
Why?
| | Nasal Mucosa | 7 | 2025 | 113 | 1.120 |
Why?
| | Allergens | 17 | 2022 | 391 | 1.020 |
Why?
| | Child | 81 | 2025 | 22980 | 1.000 |
Why?
| | Oscillometry | 4 | 2025 | 35 | 0.940 |
Why?
| | Virus Diseases | 4 | 2022 | 218 | 0.940 |
Why?
| | Endotoxins | 4 | 2013 | 217 | 0.800 |
Why?
| | Immunoglobulin E | 21 | 2020 | 316 | 0.800 |
Why?
| | Rhinitis | 5 | 2018 | 169 | 0.760 |
Why?
| | Omalizumab | 9 | 2020 | 44 | 0.750 |
Why?
| | Airway Resistance | 3 | 2025 | 38 | 0.740 |
Why?
| | Poverty | 7 | 2016 | 533 | 0.730 |
Why?
| | Adrenal Cortex Hormones | 11 | 2025 | 487 | 0.720 |
Why?
| | Child, Preschool | 41 | 2025 | 12017 | 0.700 |
Why?
| | Phenotype | 7 | 2018 | 3216 | 0.680 |
Why?
| | Air Pollution, Indoor | 3 | 2025 | 171 | 0.680 |
Why?
| | Respiratory Sounds | 9 | 2024 | 103 | 0.650 |
Why?
| | Food Hypersensitivity | 3 | 2014 | 168 | 0.640 |
Why?
| | Respiratory Function Tests | 9 | 2025 | 545 | 0.640 |
Why?
| | Hygiene | 4 | 2015 | 29 | 0.610 |
Why?
| | Bronchodilator Agents | 8 | 2025 | 187 | 0.610 |
Why?
| | Biological Products | 1 | 2023 | 258 | 0.580 |
Why?
| | Humans | 118 | 2025 | 147306 | 0.580 |
Why?
| | Inhalation Exposure | 2 | 2025 | 103 | 0.580 |
Why?
| | Rhinovirus | 9 | 2025 | 60 | 0.570 |
Why?
| | Adolescent | 47 | 2025 | 22826 | 0.550 |
Why?
| | Microbiota | 4 | 2022 | 736 | 0.530 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2018 | 81 | 0.510 |
Why?
| | Disease Progression | 14 | 2025 | 2892 | 0.490 |
Why?
| | Hygiene Hypothesis | 1 | 2015 | 1 | 0.460 |
Why?
| | Biological Therapy | 1 | 2015 | 28 | 0.450 |
Why?
| | Air Pollutants | 2 | 2025 | 407 | 0.450 |
Why?
| | Male | 69 | 2025 | 73954 | 0.410 |
Why?
| | Dust | 5 | 2021 | 92 | 0.410 |
Why?
| | Peanut Hypersensitivity | 5 | 2015 | 143 | 0.410 |
Why?
| | Prevalence | 10 | 2018 | 2889 | 0.400 |
Why?
| | Female | 70 | 2025 | 80081 | 0.400 |
Why?
| | Nitrogen Dioxide | 1 | 2013 | 45 | 0.390 |
Why?
| | Egg Hypersensitivity | 4 | 2016 | 28 | 0.380 |
Why?
| | Models, Theoretical | 1 | 2016 | 563 | 0.380 |
Why?
| | Cockroaches | 5 | 2021 | 23 | 0.380 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 91 | 0.370 |
Why?
| | Spirometry | 7 | 2024 | 235 | 0.370 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2416 | 0.360 |
Why?
| | Leukocytes, Mononuclear | 8 | 2021 | 590 | 0.360 |
Why?
| | Picornaviridae Infections | 4 | 2025 | 53 | 0.340 |
Why?
| | Epigenesis, Genetic | 6 | 2018 | 708 | 0.340 |
Why?
| | Risk Factors | 17 | 2025 | 11017 | 0.330 |
Why?
| | Nicotine | 1 | 2013 | 336 | 0.330 |
Why?
| | Disease Management | 5 | 2025 | 654 | 0.320 |
Why?
| | Hypersensitivity, Immediate | 3 | 2012 | 41 | 0.300 |
Why?
| | Arachis | 5 | 2015 | 108 | 0.300 |
Why?
| | Stress, Psychological | 1 | 2018 | 1174 | 0.290 |
Why?
| | Receptors, Pattern Recognition | 1 | 2008 | 13 | 0.280 |
Why?
| | Infant | 19 | 2024 | 10195 | 0.280 |
Why?
| | Bacterial Infections | 2 | 2008 | 247 | 0.280 |
Why?
| | Maxillary Sinus | 2 | 2009 | 11 | 0.280 |
Why?
| | Primary Health Care | 3 | 2021 | 1760 | 0.280 |
Why?
| | Environmental Monitoring | 3 | 2025 | 347 | 0.270 |
Why?
| | Common Cold | 2 | 2025 | 16 | 0.270 |
Why?
| | Gene Expression Regulation | 7 | 2025 | 2625 | 0.270 |
Why?
| | Prospective Studies | 10 | 2025 | 8166 | 0.260 |
Why?
| | Urban Health | 4 | 2013 | 96 | 0.260 |
Why?
| | Environmental Microbiology | 2 | 2007 | 47 | 0.260 |
Why?
| | Transcriptome | 5 | 2025 | 1059 | 0.250 |
Why?
| | Precision Medicine | 2 | 2021 | 464 | 0.250 |
Why?
| | Fluticasone | 6 | 2018 | 53 | 0.240 |
Why?
| | DNA Methylation | 5 | 2018 | 722 | 0.240 |
Why?
| | Immune System | 1 | 2007 | 181 | 0.240 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 2013 | 50 | 0.240 |
Why?
| | Sinusitis | 1 | 2009 | 230 | 0.230 |
Why?
| | Epithelial Cells | 3 | 2024 | 1141 | 0.230 |
Why?
| | Practice Guidelines as Topic | 7 | 2018 | 1598 | 0.230 |
Why?
| | Dermatitis, Atopic | 5 | 2014 | 322 | 0.230 |
Why?
| | Biomarkers | 6 | 2022 | 4354 | 0.230 |
Why?
| | Adrenergic beta-Agonists | 2 | 2009 | 92 | 0.230 |
Why?
| | Baltimore | 2 | 2016 | 72 | 0.220 |
Why?
| | United States | 14 | 2025 | 16313 | 0.210 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2024 | 30 | 0.210 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 1514 | 0.210 |
Why?
| | Maxillary Sinusitis | 1 | 2004 | 6 | 0.210 |
Why?
| | Recurrence | 3 | 2024 | 1151 | 0.200 |
Why?
| | Gene Expression Profiling | 5 | 2025 | 1794 | 0.200 |
Why?
| | Respiratory Tract Infections | 2 | 2019 | 399 | 0.200 |
Why?
| | Medicaid | 2 | 2024 | 475 | 0.190 |
Why?
| | Skin Tests | 7 | 2014 | 94 | 0.190 |
Why?
| | Biological Factors | 1 | 2023 | 39 | 0.190 |
Why?
| | Host-Pathogen Interactions | 2 | 2017 | 367 | 0.190 |
Why?
| | Cities | 2 | 2018 | 140 | 0.190 |
Why?
| | Maternal Exposure | 2 | 2018 | 190 | 0.190 |
Why?
| | Immunity, Innate | 1 | 2008 | 840 | 0.180 |
Why?
| | Eosinophils | 3 | 2019 | 319 | 0.180 |
Why?
| | Pulmonary Eosinophilia | 1 | 2022 | 27 | 0.180 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2016 | 20 | 0.180 |
Why?
| | Treatment Outcome | 14 | 2024 | 11947 | 0.180 |
Why?
| | Pulmonary Surfactants | 1 | 2023 | 105 | 0.180 |
Why?
| | Self Care | 1 | 2005 | 395 | 0.180 |
Why?
| | Forced Expiratory Volume | 5 | 2017 | 451 | 0.180 |
Why?
| | DNA, Bacterial | 1 | 2003 | 320 | 0.180 |
Why?
| | Administration, Inhalation | 6 | 2016 | 572 | 0.180 |
Why?
| | Quality of Life | 2 | 2021 | 3246 | 0.170 |
Why?
| | Milk Hypersensitivity | 2 | 2012 | 18 | 0.170 |
Why?
| | Pediatrics | 1 | 2010 | 1139 | 0.170 |
Why?
| | Early Growth Response Protein 1 | 1 | 2021 | 32 | 0.170 |
Why?
| | CpG Islands | 2 | 2018 | 176 | 0.170 |
Why?
| | Tobacco Smoke Pollution | 3 | 2016 | 227 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2022 | 1005 | 0.170 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2018 | 140 | 0.170 |
Why?
| | Housing | 4 | 2021 | 142 | 0.160 |
Why?
| | Double-Blind Method | 10 | 2016 | 2080 | 0.160 |
Why?
| | Mucin 5AC | 1 | 2021 | 71 | 0.160 |
Why?
| | Immune Tolerance | 2 | 2014 | 386 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1162 | 0.160 |
Why?
| | Quantitative Trait Loci | 3 | 2021 | 389 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2021 | 1777 | 0.160 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6164 | 0.160 |
Why?
| | Anti-Allergic Agents | 2 | 2018 | 41 | 0.160 |
Why?
| | Enterovirus Infections | 1 | 2023 | 175 | 0.160 |
Why?
| | Nitric Oxide | 4 | 2015 | 892 | 0.160 |
Why?
| | Bronchial Hyperreactivity | 3 | 2012 | 104 | 0.150 |
Why?
| | Intellectual Disability | 1 | 2021 | 183 | 0.150 |
Why?
| | Adult | 21 | 2025 | 41406 | 0.150 |
Why?
| | Androstadienes | 3 | 2009 | 77 | 0.150 |
Why?
| | ERG1 Potassium Channel | 1 | 2018 | 6 | 0.140 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 6 | 0.140 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 6011 | 0.140 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.140 |
Why?
| | Albuterol | 4 | 2025 | 76 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 471 | 0.140 |
Why?
| | Genotype | 2 | 2021 | 1875 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2018 | 54 | 0.130 |
Why?
| | Respiratory System | 1 | 2019 | 150 | 0.130 |
Why?
| | Eczema | 2 | 2010 | 66 | 0.130 |
Why?
| | Nutrition Surveys | 4 | 2014 | 279 | 0.130 |
Why?
| | Acute Disease | 1 | 2020 | 1049 | 0.130 |
Why?
| | Lipopolysaccharides | 3 | 2008 | 863 | 0.130 |
Why?
| | Interleukin-6 | 2 | 2020 | 784 | 0.130 |
Why?
| | Age of Onset | 2 | 2016 | 568 | 0.130 |
Why?
| | Seasons | 5 | 2022 | 540 | 0.120 |
Why?
| | RNA Virus Infections | 1 | 2017 | 19 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2019 | 512 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2025 | 2458 | 0.120 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 7 | 0.120 |
Why?
| | Immunization | 2 | 2016 | 375 | 0.120 |
Why?
| | Age Factors | 4 | 2006 | 3372 | 0.120 |
Why?
| | Basophils | 3 | 2015 | 52 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2021 | 590 | 0.120 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 72 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 318 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6543 | 0.120 |
Why?
| | Medical History Taking | 1 | 2016 | 119 | 0.120 |
Why?
| | Plasma Cells | 2 | 2009 | 81 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2018 | 5478 | 0.120 |
Why?
| | Antiviral Agents | 2 | 2023 | 776 | 0.120 |
Why?
| | Young Adult | 11 | 2025 | 14437 | 0.120 |
Why?
| | RNA Viruses | 1 | 2017 | 73 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2020 | 1147 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2025 | 3660 | 0.110 |
Why?
| | Cohort Studies | 6 | 2025 | 6099 | 0.110 |
Why?
| | Lung | 3 | 2023 | 4141 | 0.110 |
Why?
| | Immune System Diseases | 1 | 2015 | 40 | 0.110 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 4 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2223 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2016 | 502 | 0.110 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1342 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 445 | 0.110 |
Why?
| | Schools | 1 | 2018 | 453 | 0.110 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1496 | 0.110 |
Why?
| | Air Pollution | 1 | 2018 | 315 | 0.110 |
Why?
| | Rural Health | 2 | 2006 | 87 | 0.100 |
Why?
| | Down Syndrome | 1 | 2021 | 526 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2019 | 3029 | 0.100 |
Why?
| | Antigens, Plant | 1 | 2014 | 55 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2015 | 114 | 0.100 |
Why?
| | Dendritic Cells | 1 | 2017 | 510 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1481 | 0.100 |
Why?
| | Respiratory Hypersensitivity | 1 | 2014 | 65 | 0.100 |
Why?
| | Specimen Handling | 1 | 2015 | 183 | 0.100 |
Why?
| | Infant, Premature | 1 | 2018 | 635 | 0.100 |
Why?
| | Parents | 2 | 2022 | 1428 | 0.100 |
Why?
| | Leukotriene E4 | 2 | 2012 | 24 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 594 | 0.100 |
Why?
| | Indians, North American | 1 | 2018 | 567 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1281 | 0.100 |
Why?
| | Enterovirus | 2 | 2024 | 83 | 0.100 |
Why?
| | Animals | 10 | 2021 | 38417 | 0.100 |
Why?
| | Biopsy | 2 | 2009 | 1093 | 0.090 |
Why?
| | Research | 1 | 2016 | 435 | 0.090 |
Why?
| | Bronchiolitis | 2 | 2024 | 87 | 0.090 |
Why?
| | Neutrophils | 2 | 2009 | 1135 | 0.090 |
Why?
| | Telemedicine | 1 | 2022 | 978 | 0.090 |
Why?
| | Prognosis | 4 | 2017 | 4384 | 0.090 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2021 | 24 | 0.090 |
Why?
| | Hospitalization | 2 | 2021 | 2496 | 0.090 |
Why?
| | Homeostasis | 1 | 2015 | 651 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2018 | 1171 | 0.080 |
Why?
| | Influenza, Human | 1 | 2017 | 634 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2133 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 190 | 0.080 |
Why?
| | Obesity | 2 | 2018 | 3149 | 0.080 |
Why?
| | Decision Making | 1 | 2018 | 994 | 0.080 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2010 | 25 | 0.080 |
Why?
| | Time Factors | 3 | 2016 | 7173 | 0.080 |
Why?
| | Chronic Disease | 2 | 2009 | 1845 | 0.080 |
Why?
| | Nedocromil | 1 | 2010 | 20 | 0.080 |
Why?
| | Comorbidity | 2 | 2015 | 1672 | 0.080 |
Why?
| | Budesonide | 1 | 2010 | 49 | 0.080 |
Why?
| | Logistic Models | 3 | 2010 | 2142 | 0.080 |
Why?
| | Genomics | 1 | 2015 | 839 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 405 | 0.070 |
Why?
| | Physicians | 1 | 2018 | 961 | 0.070 |
Why?
| | Food | 1 | 2010 | 150 | 0.070 |
Why?
| | Models, Statistical | 1 | 2013 | 677 | 0.070 |
Why?
| | Hexosaminidases | 1 | 2009 | 17 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 200 | 0.070 |
Why?
| | Immunoglobulin G | 4 | 2014 | 901 | 0.070 |
Why?
| | RNA | 1 | 2015 | 916 | 0.070 |
Why?
| | Health Personnel | 1 | 2015 | 762 | 0.070 |
Why?
| | Peroxidase | 1 | 2009 | 168 | 0.070 |
Why?
| | Staining and Labeling | 1 | 2009 | 153 | 0.070 |
Why?
| | Natural Killer T-Cells | 1 | 2009 | 71 | 0.070 |
Why?
| | DNA | 1 | 2015 | 1444 | 0.070 |
Why?
| | Exhalation | 3 | 2015 | 29 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2008 | 69 | 0.070 |
Why?
| | Curriculum | 1 | 2015 | 1083 | 0.070 |
Why?
| | Glucocorticoids | 2 | 2011 | 537 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 928 | 0.070 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2018 | 26 | 0.060 |
Why?
| | Prednisone | 1 | 2008 | 230 | 0.060 |
Why?
| | Macrophage Activation | 1 | 2008 | 181 | 0.060 |
Why?
| | Gene Frequency | 2 | 2021 | 498 | 0.060 |
Why?
| | Infant Care | 1 | 2007 | 44 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 593 | 0.060 |
Why?
| | Community Health Nursing | 1 | 2007 | 63 | 0.060 |
Why?
| | Dexamethasone | 2 | 2025 | 368 | 0.060 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 443 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2009 | 430 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1122 | 0.060 |
Why?
| | Manure | 1 | 2006 | 7 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2018 | 1225 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2009 | 575 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2025 | 17561 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2011 | 781 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 116 | 0.060 |
Why?
| | Electronics, Medical | 1 | 2005 | 7 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 217 | 0.060 |
Why?
| | Environment | 1 | 2007 | 297 | 0.060 |
Why?
| | India | 1 | 2006 | 221 | 0.060 |
Why?
| | Antigens, CD | 1 | 2009 | 562 | 0.060 |
Why?
| | Bronchial Provocation Tests | 1 | 2005 | 47 | 0.060 |
Why?
| | Risk Assessment | 2 | 2006 | 3784 | 0.060 |
Why?
| | Interferon-alpha | 2 | 2017 | 201 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 723 | 0.050 |
Why?
| | Patient Compliance | 1 | 2009 | 591 | 0.050 |
Why?
| | Salmeterol Xinafoate | 2 | 2018 | 20 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1158 | 0.050 |
Why?
| | Virus Attachment | 1 | 2024 | 19 | 0.050 |
Why?
| | Middle Aged | 7 | 2025 | 36821 | 0.050 |
Why?
| | Exocrine Glands | 1 | 2004 | 5 | 0.050 |
Why?
| | Basement Membrane | 1 | 2004 | 32 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 24 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 789 | 0.050 |
Why?
| | Leukotrienes | 1 | 2004 | 28 | 0.050 |
Why?
| | Macrophages | 2 | 2009 | 1530 | 0.050 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2003 | 9 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 626 | 0.050 |
Why?
| | Interleukin-13 | 2 | 2015 | 149 | 0.050 |
Why?
| | Administration, Sublingual | 2 | 2013 | 13 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2018 | 4170 | 0.050 |
Why?
| | Viral Load | 1 | 2025 | 528 | 0.050 |
Why?
| | Cell Count | 1 | 2004 | 321 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 878 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2003 | 115 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2006 | 420 | 0.050 |
Why?
| | Agriculture | 1 | 2003 | 94 | 0.050 |
Why?
| | Administration, Topical | 1 | 2003 | 156 | 0.050 |
Why?
| | Protein Subunits | 1 | 2003 | 229 | 0.050 |
Why?
| | Cysteine | 1 | 2004 | 211 | 0.050 |
Why?
| | Breast Feeding | 1 | 2006 | 447 | 0.040 |
Why?
| | Interleukin-4 | 2 | 2015 | 207 | 0.040 |
Why?
| | Epithelium | 1 | 2023 | 311 | 0.040 |
Why?
| | Particulate Matter | 1 | 2025 | 329 | 0.040 |
Why?
| | Lymphocytes | 1 | 2004 | 378 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 75 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1049 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2030 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 347 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2003 | 311 | 0.040 |
Why?
| | Nasal Provocation Tests | 1 | 2021 | 3 | 0.040 |
Why?
| | Th1 Cells | 1 | 2002 | 139 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1379 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2003 | 300 | 0.040 |
Why?
| | Fungi | 1 | 2021 | 122 | 0.040 |
Why?
| | Inflammation | 3 | 2020 | 2921 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2087 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2009 | 2017 | 0.040 |
Why?
| | Breath Tests | 2 | 2012 | 77 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 284 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 233 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 322 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1140 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 75 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 481 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2003 | 1518 | 0.040 |
Why?
| | Linear Models | 2 | 2013 | 852 | 0.040 |
Why?
| | Immunotherapy | 1 | 2004 | 672 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2018 | 17 | 0.030 |
Why?
| | Chicago | 1 | 2018 | 62 | 0.030 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2018 | 25 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2015 | 1302 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 290 | 0.030 |
Why?
| | Environmental Pollution | 1 | 2018 | 21 | 0.030 |
Why?
| | Maternal Health | 1 | 2018 | 50 | 0.030 |
Why?
| | Lipids | 1 | 2023 | 723 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 383 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2018 | 269 | 0.030 |
Why?
| | Family | 1 | 2022 | 690 | 0.030 |
Why?
| | Aged | 4 | 2025 | 26516 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 323 | 0.030 |
Why?
| | Receptors, Glucocorticoid | 1 | 2018 | 132 | 0.030 |
Why?
| | Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 3 | 0.030 |
Why?
| | Metered Dose Inhalers | 1 | 2016 | 8 | 0.030 |
Why?
| | Vital Capacity | 1 | 2017 | 293 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2017 | 93 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 198 | 0.030 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 231 | 0.030 |
Why?
| | Child Health | 1 | 2018 | 154 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 769 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5272 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2008 | 641 | 0.030 |
Why?
| | Caregivers | 1 | 2005 | 1091 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2016 | 191 | 0.030 |
Why?
| | Models, Biological | 1 | 2003 | 1772 | 0.030 |
Why?
| | Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 6 | 0.030 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2018 | 402 | 0.030 |
Why?
| | Patient Participation | 1 | 2018 | 449 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 111 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 324 | 0.030 |
Why?
| | Cross Reactions | 1 | 2014 | 130 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 210 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.020 |
Why?
| | Community Health Services | 1 | 2015 | 231 | 0.020 |
Why?
| | Th2 Cells | 1 | 2014 | 179 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 536 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1344 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 373 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2016 | 8432 | 0.020 |
Why?
| | Eggs | 1 | 2012 | 25 | 0.020 |
Why?
| | Alleles | 1 | 2015 | 909 | 0.020 |
Why?
| | Milk | 1 | 2012 | 119 | 0.020 |
Why?
| | Bronchi | 1 | 2014 | 263 | 0.020 |
Why?
| | Mexican Americans | 1 | 2013 | 119 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1084 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7276 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 742 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 895 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2791 | 0.020 |
Why?
| | Poverty Areas | 1 | 2011 | 43 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 663 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2009 | 3448 | 0.020 |
Why?
| | Drug Utilization | 1 | 2012 | 171 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 302 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 874 | 0.020 |
Why?
| | Histamine Release | 1 | 2009 | 10 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1550 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2009 | 84 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1321 | 0.020 |
Why?
| | Cell Degranulation | 1 | 2009 | 40 | 0.020 |
Why?
| | Risk | 1 | 2012 | 927 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2009 | 43 | 0.020 |
Why?
| | Critical Care | 1 | 2015 | 705 | 0.020 |
Why?
| | Acetates | 1 | 2009 | 78 | 0.020 |
Why?
| | Sulfides | 1 | 2009 | 92 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1046 | 0.020 |
Why?
| | Quinolines | 1 | 2009 | 192 | 0.020 |
Why?
| | Drug Resistance | 1 | 2008 | 145 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1912 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2007 | 67 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 522 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 751 | 0.010 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2006 | 35 | 0.010 |
Why?
| | Growth | 1 | 2006 | 49 | 0.010 |
Why?
| | Vulnerable Populations | 1 | 2007 | 177 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 539 | 0.010 |
Why?
| | Cotinine | 1 | 2005 | 77 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 2017 | 0.010 |
Why?
| | Cats | 1 | 2005 | 241 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2006 | 779 | 0.010 |
Why?
| | Algorithms | 1 | 2012 | 1868 | 0.010 |
Why?
| | Regression Analysis | 1 | 2006 | 1003 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2832 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 518 | 0.010 |
Why?
| | Program Evaluation | 1 | 2007 | 952 | 0.010 |
Why?
| | Home Care Services | 1 | 2005 | 293 | 0.010 |
Why?
| | Rats | 1 | 2009 | 5613 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2470 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2005 | 1431 | 0.010 |
Why?
| | Colorado | 1 | 2005 | 4591 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|